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Abstract
The term spondyloarthritis (SpA) is used to describe a group of inflammatory autoimmune diseases, including ankylosing
spondylitis and psoriatic arthritis, with common genetic risk factors and clinical features. SpA is clinically distinct from
rheumatoid arthritis and typically affects the spine, sacroiliac joints, entheses, and, less commonly, peripheral joints.
Although the pathogenesis of SpA is not fully understood, recent findings have identified the interleukin (IL)-17 pathway
as a key mediator of disease pathogenesis. Clinical evidence for the efficacy of IL-17A inhibition by biologic agents was
initially shown in patients with chronic plaque psoriasis, another autoimmune disease mediated by the IL-17 pathway.
Subsequently, similar positive efficacy for inhibition of IL-17A was seen in patients with ankylosing spondylitis and
psoriatic arthritis. Inhibition of IL-17A may also improve cardiovascular and metabolic comorbidities often found
in patients with SpA because studies have linked these disorders to the IL-17 pathway. In this review, we will
examine key preclinical studies that demonstrated the mechanistic role of IL-17A in the development SpA and
discuss how these observations were translated into clinical practice.
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Background
Spondyloarthritis (SpA) is a term used to describe a
group of inflammatory autoimmune diseases that share
common genetic risk factors and clinical features, in-
cluding ankylosing spondylitis (AS), psoriatic arthritis
(PsA), reactive arthritis, undifferentiated SpA, and entero-
pathic arthritis [1–6]. SpA typically affects the spine,
sacroiliac joints, entheses, and peripheral joints. Hallmark
features of SpA include enthesitis, focal inflammation,
new bone formation and cartilage ossification that may
lead to ankyloses [2, 4, 7–9]. Clinical phenotypes include
inflammatory back pain, oligoarthritis, dactylitis, and
extra-articular features such as uveitis, psoriasis, and in-
flammatory bowel disease (IBD) [5].
Worldwide estimates of the prevalence of SpA are
variable. Available data suggest that SpA is relatively
uncommon in Asian and Middle Eastern countries,
affecting less than 0.9% of adult populations, while stud-
ies in European countries report SpA prevalence of be-
tween 0.3% and 1.9% [5]. According to data from the
2009–2010 US National Health and Nutrition Examin-
ation Survey (NHANES), it is estimated that SpA affects
roughly 1% of the adult population in the US, which
corresponds to between two million and three million
people [6].
The exact pathogenesis of SpA is not well understood,
but in recent years it has become clear that cytokines as-
sociated with innate and adaptive inflammatory immune
responses play an important role in disease initiation
and progression [2, 8, 9]. Cytokines produced by T-
helper (Th)17 cells have been shown to contribute to
pathogenic features of SpA, including joint erosion and
inflammation, new bone formation, epidermal thicken-
ing, development of psoriatic skin lesions, pannus for-
mation in joint capsules, synovial inflammation, and
angiogenesis [7–12]. Specifically, preclinical studies using
models of SpA have shown that expression of genes en-
coding proinflammatory cytokines including interleukin
(IL)-17A, tumor necrosis factor (TNF)-α, and IL-23 is up-
regulated in affected joints [9, 13] and that IL-17 promotes
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osteogenesis at inflamed sites (e.g., entheses) under condi-
tions of mechanical stress, resulting in excess bone forma-
tion that is a key characteristic difference between SpA
and rheumatoid arthritis (RA), which is characterized pre-
dominantly by bone erosion and resorption [14]. As such,
the IL-17 pathway has been identified as a potential
disease-modifying target for the treatment of SpA [9, 12,
15]. This article provides a review of the pathogenesis of
SpA and the mechanistic rationales for targeting the IL-
17A pathway based on its role in inflammation, cartilage
damage, and bone changes.
Methods
Literature searches were conducted using PubMed to
identify relevant articles and these results were supple-
mented by reference checking and with the authors’
familiarity of the literature. Due to the large number of
articles discussing IL-17A in SpA, a narrative review was
deemed to be most appropriate for this manuscript.
IL-17A in the pathogenesis of SpA
IL-17 signaling has been identified as a key modulator of
synovial inflammation and joint destruction in various ar-
thropathies through its actions on synovial cells, osteo-
blasts, and chondrocytes (Fig. 1) [12]. Of the six members
of the IL-17 cytokine family, IL-17A is the most well char-
acterized, existing as a homodimer or as part of a heterodi-
mer with IL-17F [8, 15]. Cellular production of IL-17 is
complex and heterogeneous. Table 1 provides an overview
of the diverse cellular sources of this cytokine. Notably, IL-
17A and IL-17F are primarily produced by naive CD4+ T
cells that differentiate into Th17 cells in response to stimu-
lation by IL-23 [8, 16]. In addition, IL-17A is produced by
CD8+ T cells, γδ T cells, natural killer cells, mast cells, neu-
trophils, and group 3 innate lymphoid cells [8]. Binding of
IL-17A homodimers to the heterodimeric transmembrane
IL-17 receptor (IL-17RA and IL-17RC) is a potent signal
driving autoimmune inflammatory responses associated
with arthritis-related tissue damage and joint destruction,
as well as with mucocutaneous defense mechanisms against
extracellular pathogens [8, 12, 14, 17, 18]. Furthermore,
Th17 cells ( IL-17A/IL-22) and its receptor system play im-
portant roles in osteoclast-mediated bone changes and car-
tilage destruction associated with inflammatory arthritis [2,
9, 14]. The IL-17 receptor is expressed by osteoclasts, oste-
oblasts, synoviocytes, and chondrocytes, and stimulation of
IL-17A triggers Th17 cells, osteoblasts, and synovial fibro-
blasts to produce the receptor activator of nuclear factor-
κB ligand (RANKL), which plays a vital role in production
of osteoclasts and osteoclastic precursors [14].
Many basic research studies using in vitro and animal
models have helped elucidate the roles of IL-17A and re-
lated cytokines in arthritis pathogenesis. Early mouse
models of collagen-induced arthritis (CIA) identified IL-
17 as a key contributor to RANKL-induced bone erosion
and inflammatory joint destruction [19, 20]. Subse-
quently, tissue microscopy studies have shown that T
cells with high levels of IL-23 receptors are present at
the entheseal interface between tendon and bone of both
axial and peripheral articular locations [9]. When IL-23
Fig. 1 Pathogenic role of IL-17A in SpA [12]. Reprinted from Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy
Immunol. 2013;44:183–93, with permission of Springer. APC antigen-presenting cell, ICAM-1 intercellular adhesion molecule-1, IL interleukin, IFN
interferon, MMP3 matrix metalloproteinase 3, TGF transforming growth factor, RANKL receptor activator of nuclear factor-κB ligand, Th T-helper,
TNF tumor necrosis factor
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levels were increased in cell cultures of these entheses,
expression of IL-17A, IL-22, and bone morphogenic pro-
tein 7 increased, and IL-23 also induced severe enthesitis
in animal models [9]. Initially, findings from genomic
studies indicated that IL-23 receptor signaling plays a
key role in the development of SpA, psoriasis, and IBD
[21–24]. However, more recent studies in IL-17A−/−
knockout mice have clarified that IL-23-mediated stimu-
lation of IL-17A and IL-22 drives the development and
severity of enthesitis [21]. Further substantiating the role
of IL-17A in IL-23-induced local inflammation, Rein-
hardt and colleagues showed that entheseal γ/δ cell pro-
duction is increased under conditions of inflammation
and mechanical stress, stimulating production of IL-17A
at anatomic sites commonly affected in SpA (e.g., Achil-
les tendon insertion, aortic root, and ciliary body) [25].
Further supporting the role of IL-17A signaling in
the formation of pathogenic bone erosions, joint in-
flammation, and cartilage destruction, Lubberts and
colleagues [26] observed that, in a mouse model of
CIA, neutralization of endogenous IL-17A was associ-
ated with a decrease in systemic IL-6 and a reduction
in cells that tested positive for RANKL and the in-
flammatory cytokine IL-1β. In addition, Adamopoulos
and colleagues [27] observed that IL-17A gene trans-
fer in a mouse model of CIA induced the expansion
of osteoclast precursors and increased serum levels of
biomarkers associated with bone resorption, including
tartrate-resistant acid phosphatase 5b and carboxy-
terminal collagen crosslinks.
Findings consistent with the results from basic re-
search studies have been observed in several different
human studies in SpA. These studies have shown that
levels of IL-17A, IL-23, IL-6, IL-1β, IL-21, transforming
growth factor (TGF)-β, TNF-α, and interferon (IFN)γ
are increased in sera and synovial fluid of patients with
reactive arthritis, AS, and undifferentiated SpA, and that
Th17 cell levels are increased in peripheral blood sam-
ples from patients with PsA and AS [3, 28–31]. Patho-
logic Th17-cell overexpression of IL-17 has also been
observed in the gut of patients with PsA, contributing to
chronic subclinical inflammation [32].
A study from our group that highlights the role of IL-
17A signaling in inflammatory arthritis showed that ele-
vated levels of IL-17A and IL-17RA are present in synovial
tissue samples from patients with PsA and, when cultures
of these tissue samples were treated with an anti-IL-17RA
antibody, IL-17A-induced expression of IL-8, IL-6, and
matrix metalloproteinase (MMP)3 was decreased [33].
Another important study by Jansen and colleagues [34]
showed that elevated levels of IL-17-producing CD4+ T
cells are present in patients with early, active axial SpA
Table 1 Types of IL-17-producing cells [8, 12, 33, 36, 38, 76–80]
Cell type Description
Adaptive Th17 cells • A subset of activated CD4+ T helper cells that produce high levels
of IL-17A, IL-17F, and IL-22, and express IL-23R
• CD4+ TCRα/β+ Th17 cells are a well characterized source of IL-17 that play a key
role in immune inflammatory responses
Natural Th17 cells • Subset of thymic Th17 cells that acquire effector function prior
to peripheral antigen exposure
• These cells have different TCR gene usage and signaling properties
compared with conventional Th17 cells
γ/δ T cells • Potent source of innate IL-17 produced independently of IL-6
• Properties are similar to Th17 cells (e.g., expression of CCR6, IL-23R, and RORγt);
these cells also express TLR1, TLR2, and Dectin-1
• Levels of IL-17-producing γ/δ T cells increase during some types of bacterial infections
• Different subsets of γ/δ T cells in the thymus produce either IL-17 or IFNγ
• Major source of gut-protective IL-17, which acts independently from IL-23
iNKT cells • Cells that express a restricted TCR that recognizes glycolipid antigens
• May provide an alternative source of IL-17 when IL-6 is not present to stimulate Th17 cells
• IL-17+ cells express IL-23R and IL-1R1
Tc17 cells • Subset of CD8+ cells that produces IL-17
• May play a role in pathogenic skin and joint inflammation in psoriasis and PsA, respectively
ILC3s • Subset of ILCs defined by their capacity to produce IL-17A and/or IL-22
• The role of ILCs in SpA and other forms of destructive arthritis is unclear
because cell numbers are generally low
Neutrophils • Source of IL-17 in effector phase of arthritis
• Myeloperoxidase+ and CD15+ neutrophils have been identified as sources
of IL-17 in facet joints of patients with SpA
Mast cells • Primary source of IL-17+ cells in synovial fluid of patients with SpA as
a result of innate immune responses
CCR6 C-C chemokine receptor type 6, IFN interferon, IL interleukin, ILC innate lymphoid cell, iNKT cells invariant natural killer T cells, PsA psoriatic arthritis, ROR retin-
oic orphan receptor, SpA spondyloarthritis, TCR T-cell receptor, Th T-helper, TLR Toll-like receptor
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with and without magnetic resonance imaging (MRI) ab-
normalities. Furthermore, Kenna and colleagues [35] ob-
served that patients with active AS have increased levels
of circulating γδ T cells that express IL-23R and produce
IL-17, and a study by Noordenbos and colleagues [36]
showed that synovial tissue from patients with SpA has in-
creased levels of IL-17-expressing mast cells compared
with tissue from patients with RA. Interestingly, this in-
crease in IL-17 was not modulated by TNF-α blockade
[36]. These studies highlight just a few key examples of
the extensive research findings that have established IL-
17A signaling as an important pathway in the develop-
ment and progression of SpA.
Different roles of IL-17A in SpA and RA
While there are many similarities between the chronic
spinal and joint inflammation observed in patients
with RA and SpA, it is important to note that these
diseases have several unique clinical, radiologic, sero-
logic, and genetic features driven by different under-
lying pathogenic signaling pathways (Table 2) [8, 37].
Moreover, while many of the same cytokines are
present in both RA and SpA, differential expression
levels result in substantial differences in characteristic
bone changes. In RA, TNF-α is the predominant pro-
inflammatory cytokine, promoting RANKL-driven
osteoclast erosion, as well as suppression of osteoblast
formation [14]. In contrast, the IL-17A pathway plays
a predominant role in the promotion of osteoclasto-
genesis in patients with SpA, and levels of circulating
Th17 cells observed in the peripheral blood are much
higher and more consistently observed than in pa-
tients with RA. Additionally, Th17 cells isolated from
patients with SpA are more differentiated and poly-
functional than those from patients with RA [28].
These findings may be a result of different T-cell line-
ages in RA and SpA. For example, Menon and col-
leagues [38] observed that IL-17 in patients with PsA
was predominantly produced by CD8+-derived T cells
(Tc17 cells), while IL-17A-producing T cells were only
produced from the CD4+ lineage in patients with RA.
Furthermore, these authors observed that the fre-
quency of synovial fluid IL-17+CD4− T cells but not of
IL-17+CD4+ T cells was associated with clinical mea-
sures of PsA disease activity [38].
Translation of IL-17 inhibition into clinical practice
There is currently an unmet need in the treatment of
SpA [39]. Traditional disease-modifying antirheumatic
drugs (e.g., methotrexate) are ineffective in spinal in-
flammatory arthritis and AS. While the TNF-α inhibi-
tors etanercept, adalimumab, infliximab, certolizumab
pegol, and golimumab have all demonstrated efficacy
in AS and PsA, a substantial proportion of patients
either do not respond at all or respond inadequately,
while some patients are unable to tolerate these drugs
[15, 39–41]. In recent years, other therapies used to
treat RA have been investigated in AS, including the
IL-1 receptor antagonist anakinra, the IL-6 inhibitor
tocilizumab, the anti-CD20 antibody rituximab, and
the costimulatory pathway inhibitor abatacept. How-
ever, none of these agents have demonstrated a mean-
ingful clinical benefit in patients with AS [41].
It has been recognized that biologic agents with mech-
anisms of action other than TNF inhibition, which acts
upstream of newer agents, would provide valuable
Table 2 Differences between RA and SpA [8, 37]
RA SpA
• Characterized primarily by symmetric polyarthritis and
inflammation resulting in cartilage and bone destruction
• Oligo/polyarthritis is more often asymmetrical
• Axial involvement is rare • Characterized primarily by axial disease of the sacroiliac joints and spine
• More common in women than men • More common in men than women
• ACPA and RF antibodies are common • ACPA and RF antibodies are absent
• Strong genetic association with HLA-DR • Most common genetic involvement is HLA-B27
• Central clinical feature is synovitis • Affects the axial skeleton and peripheral joints with synovial involvement,
especially in entheses, bone, and bone marrow (osteitis)
• Driven by B- and/or T-cell autoreactivity • Driven by innate immune cells (e.g., macrophages, PMN cells, mast cells)
• Macrophage effectors of synovial inflammation are driven
predominantly by IFNγ
• Macrophage effectors of inflammation are driven predominantly by IL-17
• More pronounced hyperplasia of the synovial lining versus SpA • Increased vascularity versus RA
• Extra-articular features include rheumatoid nodules, vasculitis,
pneumonitis, scleritis
• Extra-articular features include IBD, psoriasis, uveitis, aortitis
• Little or no signs of tissue repair with joint damage • Joint damage is characterized by new cartilage and bone formation
(remodeling)
ACPA anti-citrullinated protein antibody, HLA human leukocyte antigen, IBD inflammatory bowel disease, IFN interferon, IL interleukin, PMN polymorphonuclear, RA
rheumatoid arthritis, RF rheumatoid factor, SpA spondyloarthritis
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alternatives for the treatment of SpA. However, until
very recently there was a lack of alternatives to TNF-α
inhibitors [39]. That changed with the approval of the
IL-12/IL-23 antagonist ustekinumab, the phospho-
diesterase 4 inhibitor apremilast, and the IL-17A inhibi-
tor secukinumab for the treatment of PsA, and with the
approval of secukinumab for the treatment of AS. Now,
when patients fail to respond to one biologic due to lack
of efficacy or poor tolerability, switching to another bio-
logic with a different mechanism of action can be an ef-
fective treatment strategy [42, 43].
When choosing a biologic agent in SpA, it is reason-
able to consider preclinical findings that support the
mechanistic rationale for targeting IL-17A. IL-17A
seems to be a more downstream effector of SpA patho-
genesis than other cytokines (i.e., IL-23, TGF-β, IL-6,
and IL-1β), which act upstream to trigger differenti-
ation of Th17 cells in entheses and synovial tissue.
Once activated, these Th17 cells stimulate production
of downstream effector cytokines including IL-17 and
IL-22, which contribute to inflammation, bone erosion,
and bone fusion [2, 7, 9, 12, 27, 28, 33]. In addition to
the good efficacy observed in SpA with this strategy,
such downstream targeting may also be beneficial for
patients with refractory SpA and those who are other-
wise intolerant to other biologic therapies.
As clinical development programs for IL-17A inhibi-
tors have progressed, findings from large-scale random-
ized controlled trials have supported the translation of
IL-17A inhibition in SpA from bench to bedside. Posi-
tive findings have been observed in clinical studies of
IL-17A inhibitors in psoriasis, PsA, and AS [44–49].
Psoriasis
The IL-17A inhibitor secukinumab is approved for the
treatment of moderate-to-severe plaque psoriasis. In
phase 3 clinical studies, secukinumab consistently pro-
vided substantial meaningful improvements in the
signs and symptoms of moderate-to-severe chronic
plaque psoriasis [44, 49]. In the pivotal ERASURE and
FIXTURE studies, more than half of patients who re-
ceived secukinumab 300 mg experienced a 90% im-
provement in Psoriasis Area and Severity Index
(PASI90) scores at week 12, compared with 1% with
placebo (ERASURE) and 21% with etanercept (FIX-
TURE) [44]. In the CLEAR phase 3 study, secukinu-
mab 300 mg demonstrated superiority compared with
ustekinumab for the primary endpoint of PASI90 at
week 16 (79.0% vs 57.6% response rates, respectively;
p < 0.0001) [49].
The IL-17A inhibitor ixekizumab was recently ap-
proved for the treatment of moderate-to-severe plaque
psoriasis. In the UNCOVER-2 and UNCOVER-3 ran-
domized controlled phase 3 studies, up to 71% of
patients treated with ixekizumab achieved PASI90 at
week 12, compared with 0.6% to 3.1% with placebo, and
18.7% to 25.7% with etanercept [45].
The anti-IL-17RA monoclonal antibody brodalumab
was in late-stage development for the treatment of
moderate-to-severe plaque psoriasis. Results of the
phase 3 AMAGINE-1 study showed that, at week 12,
PASI90 was achieved by 43% of patients treated with
brodalumab 140 mg and by 70% of patients treated
with brodalumab 210 mg, compared with 1% of pa-
tients in the placebo group [50]. In the AMAGINE-2
and AMAGINE-3 studies, brodalumab 210 mg demon-
strated higher efficacy compared with ustekinumab
based on week 12 PASI90 responses (70% vs 47% in
AMAGINE-2, and 69% vs 48% in AMAGINE-3) [51].
However, the future of brodalumab development is un-
certain based on observed events of suicidal ideation
and behavior during clinical development [52].
Psoriatic arthritis
In early 2016, secukinumab received US Food and
Drug Administration (FDA) approval for the treat-
ment of active PsA. In the large-scale FUTURE 1 and
FUTURE 2 phase 3 studies, patients received placebo
or intravenous (IV) or subcutaneous (SC) induction
dosing of secukinumab followed by SC maintenance
dosing [46, 48]. At week 24 in FUTURE 1, at least 20%
improvement in American College of Rheumatology
response criteria (ACR20) responses were observed in
50% of patients receiving secukinumab 150 mg, 51%
receiving secukinumab 75 mg, and 17% of patients re-
ceiving placebo (p < 0.001 for both comparisons with
placebo) [48]. At week 24 in FUTURE 2, which had a
mixed population of TNF-naive and TNF-experienced
patients, ACR20 was achieved by 54% of patients re-
ceiving secukinumab 300 mg (p < 0.0001), 51% receiv-
ing secukinumab 150 mg (p < 0.0001), 29% receiving
secukinumab 75 mg (p = 0.0399), and 15% of patients
receiving placebo [46]. These improvements were sus-
tained through 52 weeks of treatment [46, 48].
In the phase 3 SPIRIT-P1 trial of a TNF-naive popu-
lation, significantly more patients achieved ACR20
with ixekizumab 80 mg once every 2 weeks (62%) and
ixekizumab 80 mg once every 4 weeks (58%) than with
placebo (30%; both p ≤ 0.001) [53]. A clinical trial of
ixekizumab in biologic-experienced patients with ac-
tive PsA is ongoing (NCT02349295).
Ankylosing spondylitis
Secukinumab also recently received FDA approval for the
treatment of active AS. In a randomized, double-blind,
phase 2 study, 59% of patients treated with secukinumab
achieved rapid, meaningful clinical improvement in AS
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symptoms compared with 24% of patients who received
placebo [54]. These improvements were maintained for
up to 2 years in patients who continued in an open-label
extension of this study [55]. The benefits of secukinumab
in patients with AS were confirmed in the phase 3 MEAS-
URE 1 and MEASURE 2 studies [47]. In these randomized
controlled trials, patients received placebo, or IV or SC
loading doses of secukinumab followed by SC mainten-
ance dosing. In MEASURE 1 and MEASURE 2, respect-
ively, at least 20% improvement in Assessment of
SpondyloArthritis International Society (ASAS20) re-
sponse rates at week 16 were 61% in both studies in the
secukinumab 150 mg group, 60% and 41% in the secuki-
numab 75 mg group, and 29% and 28% for patients who
received placebo [47]. Improvement in signs and symp-
toms of AS occurred rapidly with secukinumab and were
sustained over time. Secukinumab was also associated
with improvements in physical functioning and health-
related quality of life compared with placebo [47].
Studies of ixekizumab in biologic treatment-naive
(COAST-V) and treatment-experienced (COAST-W)
patients with AS are ongoing (NCT02696785 and
NCT02696798).
Rheumatoid arthritis
As suggested by basic research studies characterizing the
different roles of IL-17A in RA and SpA [38], results
from clinical studies of IL-17A inhibitors in RA indicate
that these agents may have limited therapeutic efficacy
in this patient population [56, 57]. In separate phase 2
studies of secukinumab and ixekizumab in patients with
RA, ACR20 response rates differed across the dose
ranges studied, without a consistent dose–response rela-
tionship [56, 57]. In a 16-week phase 2 study of secuki-
numab, ACR20 response rates ranged from 36% to 54%
in the active-treatment arms, compared with 34% with
placebo [56]. In a second 52-week phase 2 study of secu-
kinumab, ACR20 response rates were not significantly
different between secukinumab and placebo (42.9% vs
40.9%), but significant improvements were observed in
the secukinumab arm based on 28-joint Disease Activity
Score (DAS28), global assessments of disease activity,
pain assessments, and high-sensitivity C-reactive protein
levels [58].
Among biologic treatment-naive patients in a phase 2
study of ixekizumab, ACR20 response rates ranged from
43% to 70%, compared with 35% for placebo. In this
study, ACR20 response rates were significantly higher
with ixekizumab 80 mg and 180 mg compared with pla-
cebo for patients with prior inadequate response to
TNF-α inhibitors [57]. Patients in this study were eligible
to enter a 48-week open-label extension. Patients in the
extension who experienced clinical improvements
during the initial 16-week study generally maintained
these improvements through week 64 [59].
Based on findings from these phase 2 studies, it cannot
be ruled out that a subset of patients with RA may ex-
perience clinical benefits from treatment with IL-17A in-
hibitors. However, a recent study investigating the
relationship between genetic biomarkers and secukinu-
mab treatment response in patients with RA found that
the human leukocyte antigen (HLA)-DRB1*04 and
HLA-DRB1* shared epitope allelic groups were not pre-
dictive of treatment response [60].
Safety profiles of secukinumab and ixekizumab
IL-17A inhibitors have been shown to have good overall
safety profiles [61]. In psoriasis clinical trials, secukinu-
mab’s side-effect profile was similar to that of the TNF-α
inhibitor etanercept and the IL-12/IL-23 antagonist uste-
kinumab, with no safety signals indicating an increased
risk for serious adverse events of interest, including ma-
lignancy, infection, or induction of autoimmune diseases
[44, 49]. In placebo-controlled studies of secukinumab
in PsA and AS, the incidence and types of adverse events
were similar between secukinumab and placebo, with a
small increased risk for infections, including candidiasis
[46–48]. Similarly, in the UNCOVER-2 and UNCOVER-
3 psoriasis clinical studies, rates of serious adverse
events were low and similar with ixekizumab and etaner-
cept, and a small number of Candida infections were re-
ported [45].
Management of comorbidities and extra-articular mani-
festations of SpA
It has been hypothesized, based on findings from recent
research, that IL-17A inhibition may have beneficial ef-
fects on some of the common comorbidities observed in
patients with SpA, as well as extra-articular symptoms
of the disease, including uveitis and psoriasis [62]. Based
on available data, Golden and colleagues [63] have spec-
ulated that the inflammation associated with increased
levels of Th17 cells and their associated cytokines may
initiate or worsen comorbidities, including atheroscler-
osis and metabolic syndrome; thus, it is logical to
hypothesize that SpA treatments that modulate inflam-
matory responses in the Th17 pathway could have added
benefits related to improvements in comorbidities.
In experiments performed by Barry and colleagues,
prolonged elevations in IL-17RA, IL-17A, and IL-17F
levels following myocardial ischemia/reperfusion in-
jury in rats contributed to permanent cardiac damage
[64]. In vivo experiments also showed that IL-17
neutralization reduced necrotic and apoptotic myocyte
death, suggesting beneficial effects following human
myocardial infarction [64].
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Preclinical studies have linked increased IL-17 produc-
tion with development of hypertension and endothelial
dysfunction through promotion of oxidative stress in the
kidneys and vasculature [65, 66]. These findings are sup-
ported by results from a clinical study that showed
serum IL-17 levels were significantly higher in patients
with prehypertension compared with normotensive con-
trols [67]. Additionally, Hautefort and colleagues [68]
observed that monocyte-derived dendritic cells in pa-
tients with idiopathic pulmonary arterial hypertension
induced greater activation and proliferation of CD4+-de-
rived Th17 cells, resulting in higher levels of IL-17 com-
pared with controls.
In a large-scale, case-controlled, genetic screening
study in patients with coronary artery disease (CAD),
Zhang and colleagues [69] found a significant association
between specific IL17A single nucleotide polymorphisms
(SNPs) and risk of CAD and acute myocardial infarction
in a Chinese Han population. Similarly, Vargas-Alarcón
and colleagues [70] found associations between two
IL17A haplotypes and development of premature CAD
in a Mexican population. In the group that developed
premature CAD, polymorphisms were also associated
with increased risks for central obesity, increased
visceral abdominal fat, and metabolic syndrome. Inter-
estingly, such increased risks for obesity may contribute
to disease pathogenesis in SpA because activated white
adipose tissue stimulates production of IL-17 and other
proinflammatory cytokines [71].
In a randomized, placebo-controlled, phase 2a trial of
patients with moderate-to-severe Crohn’s disease, IL-
17A inhibition with secukinumab did not meet its pri-
mary endpoint, and worsening of Crohn’s disease was
experienced by some patients [72]. However, in mechan-
istic studies, mixed findings have been reported for the
role of IL-17 in the gut with both protective and proin-
flammatory effects observed [73] and additional research
is required to fully understand the role of IL-17 in the
gut. Although Crohn’s disease has been reported in pa-
tients with AS treated with IL-17 inhibitors, a small
number of individuals were affected (incidence rate of
0.7 cases per 100 patient-years in pooled secukinumab-
group data from MEASURE 1 and MEASURE 2) [47].
Furthermore, in large, pooled studies of patients with
psoriasis treated with IL-17 inhibitors, IBD was reported
infrequently (incidence rate of 0.33 cases per 100
patient-years with secukinumab and incidence rate of
2.9 cases per 1000 patient-years with ixekizumab) [74,
75]. The risk of IBD with IL-17 inhibition is minimal.
Conclusions
In summary, there is ample evidence supporting the
central role of IL-17A-secreting cells in inflammation,
bone resorption/remodeling, and cartilage damage
associated with SpA, and there are strong mechanistic
rationales for targeting this pathway in SpA disease
management. Findings from clinical studies support
these rationales and indicate that biologic IL-17A inhibi-
tors may provide effective and well-tolerated alternatives
to other approved treatments for the management of
SpA.
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